68766-96-1

Basic information

• Product Name: Ethyl D-(-)-pyroglutamate
• Synonyms: D-Pyroglutamic ethyl ester;(R)-5-Oxoproline ethyl ester, D-5-Oxo-2-pyrrolidinecarboxylic acid ethyl ester;(R)-5-Oxoproline ethyl ester, D-5-Oxo-2-pyrrolidinecarboxylic acid ethyl ester, D-Pyroglutamic acid ethyl ester, Ethyl 5-oxo-D-proline, Ethyl pyroglutamate;Ethyl D-(-)-pyroglutamate;(2R)-5-Oxo-2β-pyrrolidinecarboxylic acid ethyl ester;(R)-5-Oxo-2-pyrrolidinecarboxylic acid ethyl ester;Ethyl (R)-(-)-2-pyrrolidone-5-carboxylate,99%;Ethyl (R)-(-)-2-pyrrolidone-5-carboxylateD(-)-Pyroglutamic acid ethyl esterEthyl (R)-(-)-pyroglutamateEthyl D(-)-pyroglutamate
• CAS NO: 68766-96-1
• Molecular Formula: C₇H₁₁NO₃
• Molecular Weight: 157.17
• Product Categories: Chiral Reagents;Heterocycles;Miscellaneous Reagents
• Mol File: 68766-96-1.mol
• Article Data: 12

Chemical Properties

• Melting Point: 53-57 °C
• Boiling Point: 176 °C12 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: waxy solid
• Density: 1.2483 (rough estimate)
• Vapor Pressure: 0.000519mmHg at 25°C
• Refractive Index: n20/D 1.478(lit.)
• Storage Temp.: 0-6°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 14.78±0.40(Predicted)
• BRN: 82622
• CAS DataBase Reference: Ethyl D-(-)-pyroglutamate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl D-(-)-pyroglutamate(68766-96-1)
• EPA Substance Registry System: Ethyl D-(-)-pyroglutamate(68766-96-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 37/39-26
• WGK Germany: 3
• F: 3-10
• Hazardous Substances Data: 68766-96-1(Hazardous Substances Data)

Usage

Chemical Properties

Waxy Solid

Uses

(R)-(-)-5-Ethylcarboxyl-2-pyrrolidinone (cas# 68766-96-1) is a compound useful in organic synthesis.

InChI:InChI=1/C7H11NO3/c1-2-11-7(10)5-3-4-6(9)8-5/h5H,2-4H2,1H3,(H,8,9)/t5-/m1/s1

Upstream product

• 64-17-5 ethanol 
• 6893-26-1 D-Glutamic acid 
• 4042-36-8 D-pyrrolidone-5-carboxylic acid 
• 13107-55-6 D-glutamic acid diethyl ester 
• 16450-41-2 L-glutamic acid diethyl ester 

Downstream Products

• 66673-40-3 (R)-5-hydroxymethylpyrrolidin-2-one 
• 138629-31-9 (R)-4-tert-Butoxycarbonylamino-5-(tert-butyl-diphenyl-silanyloxy)-pentanoic acid 
• 138629-37-5 (S)-2-Acetylamino-3-[1-benzyl-2-((S)-3-carbamoyl-3-dimethylamino-propyl)-1H-imidazol-4-yl]-propionic acid methyl ester 
• 138629-48-8 (S)-4-[4-((S)-2-Acetylamino-2-methoxycarbonyl-ethyl)-1-benzyl-1H-imidazol-2-yl]-2-dimethylamino-butyric acid 
• 138629-49-9 (S)-3-[(R)-4-Amino-5-(tert-butyl-diphenyl-silanyloxy)-pentanoyl]-4-benzyl-oxazolidin-2-one 
• 138629-36-4 (S)-4-[4-((S)-2-Acetylamino-2-methoxycarbonyl-ethyl)-1-benzyl-1H-imidazol-2-yl]-2-dimethylamino-butyric acid benzyl ester 
• 138629-32-0 [(R)-4-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-1-(tert-butyl-diphenyl-silanyloxymethyl)-4-oxo-butyl]-carbamic acid tert-butyl ester 
• 138629-35-3 (S)-4-[4-((S)-2-Azido-2-methoxycarbonyl-ethyl)-1-benzyl-1H-imidazol-2-yl]-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 138629-45-5 (S)-4-[(R)-4-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-1-hydroxymethyl-4-oxo-butylcarbamoyl]-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 138629-47-7 (S)-4-[4-((S)-2-Acetylamino-2-methoxycarbonyl-ethyl)-1-benzyl-1H-imidazol-2-yl]-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 138629-34-2 (S)-4-{1-Benzyl-4-[3-((S)-4-benzyl-2-oxo-oxazolidin-3-yl)-3-oxo-propyl]-1H-imidazol-2-yl}-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 138629-33-1 (S)-4-[(R)-4-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-1-(tert-butyl-diphenyl-silanyloxymethyl)-4-oxo-butylcarbamoyl]-2-tert-butoxycarbonylamino-butyric acid benzyl ester 
• 138629-44-4 (R)-5-(tert-butyl-diphenyl-silanyloxymethyl)-pyrrolidin-2-one 
• 138629-30-8 (5R)-5-(tert-butyldiphenylsilanyloxymethyl)-2-oxopyrrolidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Diastereoselective synthesis and biological evaluation of enantiomerically pure tricyclic indolines

Tricyclic indolines are common in both natural products and synthetic chemical probes. In this study we demonstrated that enantiomerically pure tricyclic indolines can be prepared from an inexpensive commercially available chiral starting material, pyroglutamic acid. The synthesis features a highly diastereoselective gold-catalyzed cyclization of alkyne-tethered indoles and subsequent diastereoselective reductive ring-opening reaction. Using this approach, we synthesized analogs of our previously discovered tricyclic indoline probes that possess antibacterial and resistance-modifying activity. The biological activity against methicillin-resistant Staphylococcus aureus (MRSA) of these analogues was evaluated and reported. The synthetic approach reported may be leveraged in the future to prepare diastereopure chemical probes for the determination of biological targets for drug discovery.

PROCESS FOR THE SYNTHESIS OF SUBSTITUTED GAMMA LACTAMS

The present invention provides synthetic processes for the preparation of a variety of well-defined substituted gamma lactams. The compounds that can be prepared by the process of the invention are useful for treating a variety of conditions. In some embodiments of the invention, the compounds are useful for treating ocular disorders, such as, for example, glaucoma, lowering of elevated intraocular pressure, and the like. In other embodiments, the compounds are useful for treating irritable bowel disease. In further embodiments, the compounds are useful in promoting hair growth. In still further embodiments, the compounds are useful in promoting wound healing, scar reduction, and the like.

CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS

There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP 4 sub type of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and theiruse as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.